When and How to Use Somatostatin Analogues

Endocrinol Metab Clin North Am. 2018 Sep;47(3):549-555. doi: 10.1016/j.ecl.2018.04.010. Epub 2018 Jul 11.

Abstract

Long-acting depot formulations of the currently available somatostatin analogues are considered the first-line treatment for control of hormonal excess by hormone-producing neuroendocrine tumors of the gastrointestinal tract and pancreas. These drugs are currently also considered the first-line treatment for tumor control of both hormone-producing and non-hormone-producing neuroendocrine tumors of the gastrointestinal tract and pancreas. These drugs need coupling and interaction with specific somatostatin receptor subtypes, which are expressed on the cells of neuroendocrine tumors of the gastrointestinal tract and pancreas.

Keywords: Lanreotide; Neuroendocrine; Octreotide; Pasireotide; Receptor; Somatostatin.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents, Hormonal / administration & dosage
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Hormone Antagonists / administration & dosage
  • Hormone Antagonists / therapeutic use*
  • Humans
  • Neuroendocrine Tumors / drug therapy*
  • Neuroendocrine Tumors / metabolism
  • Somatostatin / administration & dosage
  • Somatostatin / analogs & derivatives*
  • Somatostatin / therapeutic use*

Substances

  • Antineoplastic Agents, Hormonal
  • Hormone Antagonists
  • Somatostatin